Sida 1 från 75 resultat
Choledochal cysts are uncommon congenital anomalies of the biliary tree. We report a 25-year-old female who presented with palpable abdominal lump, jaundice and fever. She was diagnosed with a huge, type IVA choledochal cyst with enormous asymmetric cystic dilatation of extrahepatic segment of left
Stage IIB-IVA cancer of the cervix represents locally advanced-stage disease that has extended beyond the cervix without clinical evidence of extrapelvic metastasis. Localized surgery is seldom used as the extent of the disease precludes and an adequate surgical margin. Both sophisticated imaging
BACKGROUND
Patients with cervical carcinoma that invade the bladder or rectum (International Federation of Obstetrics and Gynecology stage IVA) have a high risk to develop vesicovaginal and/or rectovaginal fistulae. If we could identify pretreatment factors that predict fistula formation, these
BACKGROUND
Patients with advanced cervical carcinoma are treated routinely with radiotherapy and cisplatin-containing chemotherapy. It has been shown that hyperthermia can improve the results of both radiotherapy and cisplatin. In the current study, the feasibility and efficacy of the combination of
BACKGROUND
Advanced cervical cancer is routinely treated with radiotherapy and cisplatin-containing chemotherapy. Hyperthermia has been shown to improve the results of both radiotherapy and cisplatin. The feasibility of the combination of all three modalities was demonstrated and reported in a study
BACKGROUND
Quisinostat is a hydroxamate, second-generation, orally available pan-histone deacetylase inhibitor.
OBJECTIVE
To evaluate the efficacy and safety of oral quisinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL).
METHODS
Patients received quisinostat 8 mg or 12 mg
A report on a study conducted under the auspices of the Gynecologic Oncology Group on the treatment of women with advanced carcinoma of the uterine cervix (stages IIB, IIIB, IVA) with radiotherapy alone versus radiotherapy plus immunotherapy (intravenous Corynebacterium parvum) is presented. There
Several surgical procedures, from debulking to extra pleural pneumonectomy, may be applied for stage IVa Masaoka thymomas but their efficiency is still controversial. Case studies favored R0 resection as the cornerstone of multimodal therapy for loco-regional metastatic extension. We report our
BACKGROUND
For many years, the standard treatment of advanced cervical cancer has been radiotherapy (RT), including brachytherapy. The achievement of locoregional tumour control is essential for cure. Results of RT in early stages are reasonably satisfactory, but locoregional failure rates for stage
To evaluate the effectiveness of whole-pelvic hyperthermia (HT) added to standard chemoradiotherapy (CRT) in locally advanced cervical cancer (CC), by investigating the clinical response and survival of patients treated with cisplatin-based CRT vs. CRT with HT (CRT + HT).
This study was conducted at
A systematic review with conventional and network meta-analyses (NMA) was conducted to examine the outcomes of loco-regional hyperthermia (HT) with radiotherapy (RT) and/or chemotherapy (CT) in locally advanced cervix cancer, IIB-IVA (LACC).
A total of 217 abstracts were screened from five databases
OBJECTIVE
To report response rate, pelvic tumor control, survival, and late toxicity after treatment with combined radiotherapy and hyperthermia (RHT) for patients with locally advanced cervical carcinoma (LACC) and compare the results with other published series.
METHODS
From 1996 to 2005, a total
OBJECTIVE
To evaluate preoperative radiochemotherapy combined with regional pelvic hyperthermia in patients with nonresectable cervical cancer >/= International Federation of Gynecology and Obstetrics (FIGO) IIB "bulky" in a Phase II study.
METHODS
Thirty-two patients with nonresectable FIGO IIB-IVA
OBJECTIVE
The aim of our study was to evaluate the feasibility and the efficacy of cytoreductive surgery (CS) with intraoperative chemo-hyperthermia in the management of advanced stage IVA (T4N0M0) pancreatic cancer.
METHODS
From August 1995 through March 1996, seven patients with unresectable